{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kitamura N"],"funding":["The Japan Agency for Medical Research and Development"],"pagination":["00190-2018"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6421360"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(1)"],"pubmed_abstract":["The incidence and prevalence of autoimmune pulmonary alveolar proteinosis in Japan were previously estimated to be 0.49 and 6.2 per million, respectively. Thereafter, an increase in serological diagnosis forced a re-estimation of the incidence based on more contemporaneous data using more robust methods. Sera of 702 patients were positive for granulocyte-macrophage colony-stimulating factor autoantibody during the 2006-2016 period (group A). Of these patients, 43 were actively surveyed in Niigata prefecture (group B) for estimation of the incidence. To estimate the survival period, 103 patients (group C) were investigated retrospectively for the 1999-2017 period using restricted mean survival time. In group A, the number of patients diagnosed in each prefecture was closely correlated with "],"journal":["ERJ open research"],"pubmed_title":["Incidence of autoimmune pulmonary alveolar proteinosis estimated using Poisson distribution."],"pmcid":["PMC6421360"],"funding_grant_id":["15ek0109079h0001 (KN)"],"pubmed_authors":["Kitamura N","Tanaka T","Ishii H","Nakata K","Sakagami T","Ohkouchi S","Tazawa R","Takada T"],"additional_accession":[]},"is_claimable":false,"name":"Incidence of autoimmune pulmonary alveolar proteinosis estimated using Poisson distribution.","description":"The incidence and prevalence of autoimmune pulmonary alveolar proteinosis in Japan were previously estimated to be 0.49 and 6.2 per million, respectively. Thereafter, an increase in serological diagnosis forced a re-estimation of the incidence based on more contemporaneous data using more robust methods. Sera of 702 patients were positive for granulocyte-macrophage colony-stimulating factor autoantibody during the 2006-2016 period (group A). Of these patients, 43 were actively surveyed in Niigata prefecture (group B) for estimation of the incidence. To estimate the survival period, 103 patients (group C) were investigated retrospectively for the 1999-2017 period using restricted mean survival time. In group A, the number of patients diagnosed in each prefecture was closely correlated with ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Feb","modification":"2026-07-17T01:12:41.499Z","creation":"2026-07-13T03:06:57.574Z"},"accession":"S-EPMC6421360","cross_references":{"pubmed":["30895185"],"doi":["10.1183/23120541.00190-2018"]}}